Contact CSL |CSL Websites |Site Map |Glossary |

Research and Development

CSL is a global specialty biopharmaceutical company that aims to identify, develop and commercialise important, new, biotherapeutic products that save lives by preventing or treating serious medical conditions. We are committed to significantly investing in our future R&D portfolio and capabilities in the areas of plasma replacement therapies, vaccines, immunomodulators (with our ISCOMATRIX^® adjuvant) and recombinant therapeutic proteins.  

CSL includes CSL Behring, CSL Plasma, CSL Biotherapies and CSL Bioplasma. These four businesses have a heritage of outstanding contributions to medicine and human health, with more than 100 years experience in the development and manufacture of vaccines and plasma protein biotherapies. 

Our strong commitment to funding research and development of protein based medicines for unmet medical needs underpins our continued growth. CSL operates as one integrated global research and development organisation. We assemble co-ordinated global project teams that leverage core capabilities at each of our sites while maximising expertise and minimising duplication. These teams rely on a project management framework that facilitates collaboration across national and cultural boundaries.

R&D Partnerships CSL maintains strong long-standing strategic partnerships with academic institutions and other corporations in Australia, North America and Europe. These collaborative partnerships support a range of effective research programs, including both basic and applied research in plasma derived and recombinant biotechnology based product development.

R&D Briefing December 2009 (2.34Mb)
R&D Briefing Dec 2008
R&D Briefing Dec 2007
R&D Briefing Dec 2006
R&D Briefing Dec 2005
R&D Briefing Dec 2004